1 citations
,
August 2025 This study found that GLP-1 receptor agonists show potential for improving psoriasis and hidradenitis suppurativa by reducing inflammation and lesion severity, but they also pose dermatological risks such as alopecia and injection site reactions.
March 2026 in “Journal of Pharmaceutical Research” This study reviews the role of semaglutide in obesity management, emphasizing its substantial weight-loss and metabolic benefits in diverse patients, with a focus on its mechanisms, dosing, efficacy, and safety.
4 citations
,
March 2025 in “Journal of Cosmetic Dermatology” This study highlights a potential association between semaglutide, a diabetes medication, and increased reports of hair loss, with researchers calling for more rigorous clinical trials to confirm and better understand the risk.
In this case study, a patient developed a rash consistent with acute generalized exanthematous pustulosis after increasing the dose of semaglutide, suggesting that the reaction was likely due to the excipient propylene glycol, highlighting the importance of ingredient analysis and multidisciplinary collaboration for patient safety.
September 2025 in “Cureus” This review suggests that GLP-1 receptor agonists may improve various dermatologic conditions, but larger studies are needed to confirm these findings.